CADTH

Gilde Healthcare establishes world-leading Impact Council

Retrieved on: 
Tuesday, November 29, 2022
Newton, GDP, Medical Products Agency (Sweden), Pharmaceutical industry, European Medicines Agency, Mass, Patient, Private equity, Conditional sentence, NICE, Policy, Union, Medicines Discovery Catapult, Hospital, Health care, Massachusetts General Hospital Psychiatry Academy, Harvard Medical School, EMA, Medtech, Newton-Wellesley Hospital, Pharmacist, Executive Committee, ICER, Association of British HealthTech Industries, Association of the British Pharmaceutical Industry, Assistant, CADTH, Tufts Medical Center, General partnership, Division, Medical device, Management, Health insurance, Medicine, Humana

UTRECHT, Netherlands, Nov. 29, 2022 /PRNewswire/ -- Gilde Healthcare, the specialized healthcare investor with 2 billion raised in dedicated sector funds, today announced the establishment of the Gilde Healthcare Impact Council.

Key Points: 
  • UTRECHT, Netherlands, Nov. 29, 2022 /PRNewswire/ -- Gilde Healthcare, the specialized healthcare investor with 2 billion raised in dedicated sector funds, today announced the establishment of the Gilde Healthcare Impact Council.
  • Chaired by Professor Guido Rasi, former Executive Director of the European Medicines Agency (EMA), the Impact Council will play a pivotal role in assessing the impact on the healthcare system by Gilde Healthcare and its Venture&Growth portfolio companies.
  • Joep Muijrers, General Partner at Gilde Healthcare and responsible within Gilde Healthcare for coordinating the Impact Council, commented: "We are honoured to be working with such an established and experienced group of experts.
  • Pieter van der Meer, Managing Partner at Gilde Healthcare commented: "The Impact Council demonstrates our commitment to effectuate change in the healthcare sector.

Gilde Healthcare establishes world-leading Impact Council

Retrieved on: 
Tuesday, November 29, 2022
Newton, GDP, Medical Products Agency (Sweden), Pharmaceutical industry, European Medicines Agency, Mass, Patient, Private equity, Conditional sentence, NICE, Policy, Union, Medicines Discovery Catapult, Hospital, Health care, Massachusetts General Hospital Psychiatry Academy, Harvard Medical School, EMA, Medtech, Newton-Wellesley Hospital, Pharmacist, Executive Committee, ICER, Association of British HealthTech Industries, Association of the British Pharmaceutical Industry, Assistant, CADTH, Tufts Medical Center, General partnership, Division, Medical device, Management, Health insurance, Medicine, Humana

UTRECHT, Netherlands, Nov. 29, 2022 /PRNewswire/ -- Gilde Healthcare, the specialized healthcare investor with 2 billion raised in dedicated sector funds, today announced the establishment of the Gilde Healthcare Impact Council.

Key Points: 
  • UTRECHT, Netherlands, Nov. 29, 2022 /PRNewswire/ -- Gilde Healthcare, the specialized healthcare investor with 2 billion raised in dedicated sector funds, today announced the establishment of the Gilde Healthcare Impact Council.
  • Chaired by Professor Guido Rasi, former Executive Director of the European Medicines Agency (EMA), the Impact Council will play a pivotal role in assessing the impact on the healthcare system by Gilde Healthcare and its Venture&Growth portfolio companies.
  • Joep Muijrers, General Partner at Gilde Healthcare and responsible within Gilde Healthcare for coordinating the Impact Council, commented: "We are honoured to be working with such an established and experienced group of experts.
  • Pieter van der Meer, Managing Partner at Gilde Healthcare commented: "The Impact Council demonstrates our commitment to effectuate change in the healthcare sector.

VABYSMO® (faricimab injection) receives positive CADTH recommendation for the treatment of Diabetic Macular Edema (DME) in adults

Retrieved on: 
Thursday, November 3, 2022
Immunoglobulin G, Planetary Missions Program Office, Reading, CNIB Foundation, Medication, Visual impairment, Prevalence, Diabetic retinopathy, Retina, Macular edema, Element, Blood, CADTH, Injection, Patient, Quality of life, McMaster University, Hindawi (publisher), Heart, Diabetes, American Journal, Diagnosis, Science, Observational study, National Eye Institute, DME, Neovascularization, Research, Review, Artificial intelligence, Eye, Roche, CDEC, Severe cognitive impairment, Infection, Swelling, Central nervous system, Vascular endothelial growth factor A, Macular degeneration, Pharmaceutical industry, Publishing, Faricimab, Ophthalmology

Roche Canada is delighted that CADTH has recognized the clinical evidence and benefit shown by VABYSMO for use in Canadians living with DME.

Key Points: 
  • Roche Canada is delighted that CADTH has recognized the clinical evidence and benefit shown by VABYSMO for use in Canadians living with DME.
  • This milestone marks the second positive recommendation for VABYSMO, following the recent recommendation from CADTH for the treatment of neovascular (wet) age-related macular degeneration in September 2022.
  • "Costs And Quality Of Life In Diabetic Macular Edema: Canadian Burden Of Diabetic Macular Edema Observational Study (C-REALITY)".Journal Of Ophthalmology, 2014.
  • "Costs And Quality Of Life In Diabetic Macular Edema: Canadian Burden Of Diabetic Macular Edema Observational Study (C-REALITY)".Journal Of Ophthalmology, 2014.

CADTH Releases Its Annual List of Health Technology Trends to Watch

Retrieved on: 
Friday, March 18, 2022
Method, Neoplasm, Human, Biomarker, Literature, DNA, Public health, Ada, Point-of-care testing, Artificial intelligence, PSP, Clinical Interventions in Aging, CADTH, Technology, Industry, Time, COVID-19, Genetic variation, Medical device, HIV, Social media, Patient, Pharmaceutical industry, Vaccine, Health insurance

CADTH's 2022 Health Technology Trends to Watch report is an evidence-informed watch list that identifies and assesses emerging health technology trends and their implications.

Key Points: 
  • CADTH's 2022 Health Technology Trends to Watch report is an evidence-informed watch list that identifies and assesses emerging health technology trends and their implications.
  • "CADTH's annual watch list identifies the emerging trends health system leaders need to know about today, so they can readily adapt tomorrow."
  • Voice technology has many applications, including conversational AI technology (e.g.,chatbots)that act as voice assistants for health assessment, diagnostics, and even companionship for patients.
  • For more information, visit our 2022 Health Technology Trends to Watch website and continue the discussion on social media using #CADTHTrends.

Health Canada Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab)

Retrieved on: 
Thursday, March 10, 2022
Risk, Pharmacokinetics, CADTH, Neuroscience, Central retinal vein occlusion, CNV, Diabetic retinopathy, Samsung, Nobel Prize, LinkedIn, Safety, AMD, United Kingdom, Infliximab, Regulatory affairs, GLOBE, Patient, NOC, Macular edema, Neovascularization, RVO, Biotechnology, Inclusion, Lists of diseases, Health Canada, Pathology, General manager, Endocrinology, Culture, Visual impairment, Trastuzumab, Treatment, Ophthalmology, Multiple sclerosis, Hematology, Twitter, Ranibizumab, Adalimumab, Spinal muscular atrophy, Severe cognitive impairment, Bevacizumab, Gastroenterology, Choroidal neovascularization, Social media, Biosimilar, Health care, Genentech, DME, Generic drug, Pharmaceutical industry, Health insurance, EU, Biogen, Woman

Health Canada granted a Notice of Compliance (NOC) for BYOOVIZ on March 8, making it the first and only ranibizumab biosimilar to receive regulatory approval in Canada to date.

Key Points: 
  • Health Canada granted a Notice of Compliance (NOC) for BYOOVIZ on March 8, making it the first and only ranibizumab biosimilar to receive regulatory approval in Canada to date.
  • The approval is part of our commitment to providing a treatment option for patients with retinal vascular disorders in Canada.
  • The Health Canada approval was based on a totality of evidence including quality, non-clinical data, and clinical data.
  • In November 2019, Samsung Bioepis signed a commercialization agreement with Biogen Inc. for two ophthalmology biosimilar candidates, SB11 (ranibizumab) and SB15 (aflibercept).

New PMPRB report shows significant consistency in public drug plan coverage across Canada for drugs subject to "Common Drug Review" process

Retrieved on: 
Tuesday, February 22, 2022
PMPRB, Gaps, Patented Medicine Prices Review Board, CADTH, CDR, Degenerative disease, Health insurance, Pharmaceutical industry, Generic drug

This report compares formulary coverage across Canada's public drug plans for 307 medicines reviewed by the Canadian Agency for Drugs and Technologies in Health (CADTH)'s Common Drug Review (CDR) process between December 16, 2003, and June 30, 2019.

Key Points: 
  • This report compares formulary coverage across Canada's public drug plans for 307 medicines reviewed by the Canadian Agency for Drugs and Technologies in Health (CADTH)'s Common Drug Review (CDR) process between December 16, 2003, and June 30, 2019.
  • The findings from this report show that reimbursement for CDR-reviewed medicines is fairly consistent across most of Canada's public drug plans.
  • Most notably, with the exception of a few smaller public drug programs, listing rates for expensive drugs for rare diseases were higher than those for other CDR medicines.
  • Expensive drugs for rare diseases (EDRDs) had higher listing rates than other CDR-reviewed medicines in most of the larger public drug plans.

CADTH Establishes New Post-Market Drug Evaluation Program

Retrieved on: 
Friday, February 4, 2022
Sentinel Initiative, Safety, Public, Canadian Institutes of Health Research, Program, Uncertainty, Intention, Center for Drug Evaluation and Research, CIHR, US, Drug Safety, Center, CADTH, Network, Health Canada, FDA, Data analysis, Pharmaceutical industry, Tutoring, Medical device, Health insurance, Pharmacoepidemiology, Pharmacovigilance

OTTAWA, ON, Feb. 4, 2022 /CNW/ -CADTH is pleased to announce it is expanding its expertise in the management of pharmaceuticals in Canada with the creation of a new Post-Market Drug Evaluation (PMDE) Program.

Key Points: 
  • OTTAWA, ON, Feb. 4, 2022 /CNW/ -CADTH is pleased to announce it is expanding its expertise in the management of pharmaceuticals in Canada with the creation of a new Post-Market Drug Evaluation (PMDE) Program.
  • The PMDE Program will be responsible for launching and coordinating a network that leverages Canadian expertise in applied drug research, methodology, and data analysis.
  • "The creation of the Post-Market Drug Evaluation Program means decision-makers can turn to CADTH for advice across the life cycle of a drug, starting before a drug is approved through to its use in the real world," said CADTH President and Chief Executive Officer Suzanne McGurn.
  • On February 8, 2022 CADTH will host an information session to provide researchers and other stakeholders with details about the PMDE Program.

Sun Pharma's (Pr)ILUMYA™ (tildrakizumab injection) now available to help Canadians living with moderate-to-severe plaque psoriasis

Retrieved on: 
Thursday, October 28, 2021
Safety, Disease, Psoriasis, Gaps, CAPP, Chemokine, Agency, Interleukin, Research, Quality of life, Bleeding, Sun Pharma, Name, NSE, Joint Medical Service (Germany), BSE, Company, Investment, Tildrakizumab, Canadian Agency for Drugs and Technologies in Health, Medicine, Respiratory tract, Freedom, Skin, Light, TM, Patient, Reuters, CADTH, Headache, U.A.E, Pharmaceutical industry, Medical device, Generic drug, Sulfur, Health insurance, Fine chemical

"We are excited to introduce this important biologic treatment to Canadians living with this common, inhibiting and often-overlooked disease.

Key Points: 
  • "We are excited to introduce this important biologic treatment to Canadians living with this common, inhibiting and often-overlooked disease.
  • "With five years of effective treatment of moderate-to-severe plaque psoriasis, ILUMYA demonstrates our commitment to providing innovative medicines to support patient lifestyle and physician choice."
  • It affects approximately one million Canadians.i Moderate-to-severe plaque psoriasis affects about 35% of patients.ii A key challenge is that many treatments stop working overtime and symptoms return.
  • "Our patients need options for an effective, durable and continuous treatment in Canada and ILUMYA will help meet that need."